Inhibikase Therapeutics, Inc. (IKT)
Nasdaq: IKT · Biological Products, (No Diagnostic Substances) · Wilmington, DE · filing with the SEC since 2018
Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 20269 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Inhibikase Therapeutics, Inc.’s names, not what it holds today.
Patents granted
9
9 utility, 1976 to Dec 31, 2025
Granted in 2025
none
Against none in 2024 and 1 in 2023
Applications published
11
1 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals3
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
Inhibikase Therapeutics, Inc. its own name
US, as the owner printed on each patent
2 published
Inhibikase Therapeutics, Inc. its own name
named as the applicant on its applications, in US
9 published
Newest grantseach row opens the USPTO’s own copy
| Granted | Patent | Title | Field | Owner as printed |
|---|---|---|---|---|
| Aug 15, 2023 | 11,725,005 | Compositions and methods for inhibiting kinases | Pharmaceuticals | Inhibikase Therapeutics, Inc. |
| Aug 9, 2022 | 11,407,747 | Compositions and methods for inhibiting kinases | Pharmaceuticals | Inhibikase Therapeutics, Inc. |
| Feb 2, 2021 | 10,906,896 | Compositions and methods for inhibiting kinases | Pharmaceuticals | Inhibikase Therapeutics, Inc. |
| Jul 9, 2019 | 10,344,027 | Compositions and methods for inhibiting kinases | Pharmaceuticals | Inhibikase Therapeutics, Inc. |
| Jun 11, 2019 | 10,316,031 | Compositions and methods for inhibiting kinases | Pharmaceuticals | Inhibikase Therapeutics, Inc. |
| Nov 6, 2018 | 10,118,923 | Compositions and methods for inhibiting kinases | Pharmaceuticals | Inhibikase Therapeutics, Inc. |
| Mar 6, 2018 | 9,907,796 | Methods of treating tumoral diseases, or bacterial or viral infections | Pharmaceuticals | Inhibikase Therapeutics, Inc. |
| Nov 28, 2017 | 9,828,370 | Compositions and methods for inhibiting kinases | Pharmaceuticals | Inhibikase Therapeutics, Inc. |
| Nov 8, 2016 | 9,487,500 | Compounds and compositions thereof | Pharmaceuticals | Inhibikase Therapeutics, Inc. |
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|---|---|---|---|
| Aug 7, 2025 | 2025/0250266 | COMPOSITIONS AND METHODS FOR INHIBITING KINASES | Pharmaceuticals | Inhibikase Therapeutics, Inc. |
| May 25, 2023 | 2023/0159514 | COMPOSITIONS AND METHODS FOR INHIBITING KINASES | Pharmaceuticals | Inhibikase Therapeutics, Inc. · patent 11,725,005 granted from it |
| May 6, 2021 | 2021/0130343 | COMPOSITIONS AND METHODS FOR INHIBITING KINASES | Pharmaceuticals | Inhibikase Therapeutics, Inc. · patent 11,407,747 granted from it |
| Feb 13, 2020 | 2020/0046699 | COMPOSITIONS AND METHODS FOR INHIBITING KINASES | Pharmaceuticals | Inhibikase Therapeutics, Inc. |
| Jan 30, 2020 | 2020/0031819 | COMPOSITIONS AND METHODS FOR INHIBITING KINASES | Pharmaceuticals | Inhibikase Therapeutics, Inc. · patent 10,906,896 granted from it |
| Apr 25, 2019 | 2019/0119266 | COMPOSITIONS AND METHODS FOR INHIBITING KINASES | Pharmaceuticals | Inhibikase Therapeutics, Inc. · patent 10,344,027 granted from it |
| Feb 21, 2019 | 2019/0055234 | COMPOSITIONS AND METHODS FOR INHIBITING KINASES | Pharmaceuticals | Inhibikase Therapeutics, Inc. · patent 10,316,031 granted from it |
| Mar 1, 2018 | 2018/0057488 | COMPOSITIONS AND METHODS FOR INHIBITING KINASES | Pharmaceuticals | Inhibikase Therapeutics, Inc. · patent 10,118,923 granted from it |
| Oct 27, 2016 | 2016/0311816 | COMPOSITIONS AND METHODS FOR INHIBITING KINASES | Pharmaceuticals | Inhibikase Therapeutics, Inc. · patent 9,828,370 granted from it |
| Apr 14, 2016 | 2016/0101106 | METHODS FOR TREATING HCV INFECTION | Pharmaceuticals | Inhibikase Therapeutics, Inc. |
What it applied for, 2024 to 2025: Pharmaceuticals 1.
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.